ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

LPCN Lipocine Inc

4.7983
0.2483 (5.46%)
Apr 26 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Lipocine Inc LPCN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.2483 5.46% 4.7983 23:00:00
Open Price Low Price High Price Close Price Previous Close
4.52 4.38 4.8099 4.7977 4.55
more quote information »

Recent News

Date Time Source Heading
4/11/202406:00PRNUSLipocine Announces Positive LPCN 2401 Clinical Results..
3/28/202407:00PRNUSLipocine Announces Positive Week 52 Results from LPCN 1148..
3/25/202407:00PRNUSLipocine Announces First Cohort Dosed in Pivotal Study of..
3/07/202416:31EDGAR2Form 8-K - Current report
3/07/202407:00PRNUSLipocine Announces Financial Results for the Full Year Ended..
3/07/202405:08EDGAR2Form 8-K - Current report
3/07/202405:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
3/06/202407:00PRNUSLipocine to Present at 36th Annual Roth Conference
3/06/202405:01EDGAR2Form 8-K - Current report
2/12/202415:10EDGAR2Form 8-K - Current report
2/06/202407:00PRNUSLipocine Announces Confirmation of Dosing Regimen for..
2/02/202407:00PRNUSLipocine Announces Continued Commercialization of TLANDO®..
1/18/202407:20EDGAR2Form 8-K - Current report
1/18/202407:00PRNUSLipocine and Verity Pharma Enter into License Agreement for..
12/19/202309:00EDGAR2Form 8-K - Current report
12/19/202307:00PRNUSLipocine to Present at Biotech Showcase 2024
11/22/202315:15EDGAR2Form S-3 - Registration statement under Securities Act of..
11/13/202313:45EDGAR2Form 8-K - Current report
11/13/202313:45PRNUSLipocine Releases Late Breaking Presentation on LPCN 1148..
11/08/202312:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/08/202308:50EDGAR2Form 8-K - Current report
11/08/202307:00PRNUSLipocine Announces Financial Results for the Third Quarter..
11/01/202308:31EDGAR2Form 8-K - Current report
11/01/202307:00PRNUSLipocine to Present Clinical Data on LPCN 1148 at The Liver..
10/26/202308:35EDGAR2Form 8-K - Current report
10/26/202307:00PRNUSLipocine Completes Successful Meeting with FDA on LPCN 1154..
10/23/202318:00PRNUSLipocine to Present at the H.C. Wainwright Annual NASH..
10/06/202315:05EDGAR2Form 8-K - Current report
9/19/202315:10EDGAR2Form 8-K - Current report
9/19/202315:05PRNUSLipocine to Present at the Cantor Fitzgerald Global..
8/10/202307:35EDGAR2Form 8-K - Current report
8/10/202307:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/10/202307:00PRNUSLipocine Announces Financial Results for the Second Quarter..
7/27/202305:45EDGAR2Form 8-K - Current report
7/27/202305:30PRNUSLPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients..
6/14/202307:00PRNUSLipocine to Present at H.C. Wainwright Annual..
6/07/202307:00PRNUSLipocine to Present LPCN 1148 and LPCN 1144 at the EASL..
5/16/202306:00PRNUSPositive Topline Clinical Results Support Streamlined..
5/11/202305:00PRNUSLipocine Announces Financial Results for the First Quarter..

Your Recent History

Delayed Upgrade Clock